Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19851522&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Treatment of congenital fibrinogen deficiency: overview and recent findings Tziomalos K; Vakalopoulou S; Perifanis V; Garipidou VVasc Health Risk Manag 2009[]; 5 (ä): 843-8Afibrinogenemia is a rare bleeding disorder with an estimated prevalence of 1:1,000,000. It is an autosomal recessive disease resulting from mutations in any of the 3 genes that encode the 3 polypeptide chains of fibrinogen and are located on the long arm of chromosome 4. Spontaneous bleeding, bleeding after minor trauma and excessive bleeding during interventional procedures are the principal manifestations. We review the management of afibrinogenemia. Replacement therapy is the mainstay of treatment of bleeding episodes in these patients and plasma-derived fibrinogen concentrate is the agent of choice. Cryoprecipitate and fresh frozen plasma are alternative treatments that should be used only when fibrinogen concentrate is not available. Secondary prophylactic treatment may be considered after life-threatening bleeding whereas primary prophylactic treatment is not currently recommended. We also discuss alternative treatment options and the management of surgery, pregnancy and thrombosis in these patients. The development of new tests to identify higher risk patients and of safer replacement therapy will improve the management of afibrinogenemia in the future.|Afibrinogenemia/blood/congenital/diagnosis/*drug therapy[MESH]|Blood Coagulation Tests[MESH]|Blood Coagulation/*drug effects/genetics[MESH]|Blood Component Transfusion[MESH]|Coagulants/*therapeutic use[MESH]|Factor VIII/administration & dosage[MESH]|Female[MESH]|Fibrinogen/administration & dosage/genetics/*therapeutic use[MESH]|Hemorrhage/blood/genetics/*prevention & control[MESH]|Humans[MESH]|Male[MESH]|Mutation[MESH]|Postoperative Hemorrhage/blood/prevention & control[MESH]|Practice Guidelines as Topic[MESH]|Pregnancy[MESH]|Pregnancy Complications/blood/prevention & control[MESH]|Treatment Outcome[MESH] |
